Suppr超能文献

社会支持与临床结局的关系:HOPE 4 干预中参与者提名的治疗支持者的评估。

Relationship Between Social Support and Clinical Outcomes: An Evaluation of Participant-Nominated Treatment Supporters in the HOPE 4 Intervention.

机构信息

Faculty of Medicine, University of Ottawa, ON, Canada (A.D.).

Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada (A.D., T.M., S.I., S.Y., J.D.S.).

出版信息

Circ Cardiovasc Qual Outcomes. 2024 Apr;17(4):e009342. doi: 10.1161/CIRCOUTCOMES.122.009342. Epub 2024 Mar 5.

Abstract

BACKGROUND

The HOPE 4 trial (Heart Outcomes Prevention and Evaluation 4) investigated the effectiveness of a comprehensive, collaborative model of care, implemented in Colombia and Malaysia, which aimed to reduce cardiovascular disease risk in individuals with hypertension. One component of this intervention was the nomination of a treatment supporter, where participants could select a family member or friend to assist them with their care. The purpose of this study was to investigate the impact of these individuals on participant outcomes, as well as the relationship dynamics between participants and their treatment supporter.

METHODS

Participants in the HOPE 4 intervention group with baseline and 12 months of follow-up were included for analysis. They were divided into Every Visit (n=339) and <Every Visit (n=268) groups based on whether they had a treatment supporter for all 5 or for <5 follow-up visits, respectively. Outcomes were stratified between groups and tested for significance using a generalized linear mixed-effects model. A survey investigating participant satisfaction with their treatment supporter was administered at 12 months.

RESULTS

Groups were majority female (53% versus 62%) with a mean age of 63 and 66 years. Country of origin differed between groups (22% versus 86%; Colombia). A 15.5% ([95% CI, 6.2%-24.8%] =0.004) greater increase in statin medication use was reported in the Every Visit group at 12 months compared with the <Every Visit group. Sixty-one percent versus 48.2% of participants reported high medication adherence at 12 months (<0.003). The difference in change in systolic blood pressure between groups was not found to be significant at 12 months, though it favored the Every Visit group (-2.3 [95% CI, -6.1 to 1.5]; =0.045). The majority of survey respondents from either study group strongly agreed that having a treatment supporter positively influenced their health.

CONCLUSIONS

Long-term support from a nominated treatment supporter was associated with improved adherence, risk factor management, and medication use among individuals with hypertension.

REGISTRATION

URL: https://www.clinicaltrials.gov; Unique identifier: NCT01826019.

摘要

背景

HOPE 4 试验(心脏结局预防与评估 4)研究了一种综合、协作的护理模式在哥伦比亚和马来西亚的有效性,该模式旨在降低高血压患者的心血管疾病风险。该干预措施的一个组成部分是指定一名治疗支持者,参与者可以选择一名家庭成员或朋友来协助他们的治疗。本研究旨在调查这些人对参与者结局的影响,以及参与者与其治疗支持者之间的关系动态。

方法

纳入基线和 12 个月随访的 HOPE 4 干预组参与者进行分析。根据他们是否有治疗支持者在所有 5 次或<5 次随访中,他们被分为每次就诊(n=339)和<每次就诊(n=268)组。使用广义线性混合效应模型对组间的结局进行分层并检验其显著性。在 12 个月时进行了一项调查,以了解参与者对其治疗支持者的满意度。

结果

两组均以女性为主(53%比 62%),平均年龄分别为 63 岁和 66 岁。两组的原籍国不同(22%比 86%;哥伦比亚)。与<每次就诊组相比,每次就诊组在 12 个月时他汀类药物使用率增加了 15.5%[95%CI,6.2%-24.8%](=0.004)。61%比 48.2%的参与者在 12 个月时报告高药物依从性(<0.003)。两组间 12 个月时收缩压变化的差异无统计学意义,但每次就诊组更有利(-2.3[95%CI,-6.1 至 1.5];=0.045)。来自两个研究组的大多数调查对象都强烈认为有一个治疗支持者对他们的健康有积极影响。

结论

长期由指定的治疗支持者提供支持与高血压患者的依从性、危险因素管理和药物使用的改善相关。

注册

网址:https://www.clinicaltrials.gov;唯一标识符:NCT01826019。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验